Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

GIVING BACK IS CORE TO OUR CULTURE

GIVING BACK IS CORE TO OUR CULTURE

Committing for change through employee volunteerism

PERCIVAL BARRETTO-KO SPEAKS AT BIOPHARMA CONGRESS

PERCIVAL BARRETTO-KO SPEAKS AT BIOPHARMA CONGRESS

Running a biopharma company during a pandemic

ASTELLAS IS COMMITTED TO COMMUNITY SUPPORT

ASTELLAS IS COMMITTED TO COMMUNITY SUPPORT

We are dedicated to supporting local and global communities as part of our COVID-19 response

revised newest covid

UPDATES AND INFORMATION

Find out how we're responding to our patients, our employees and our community

1

2

3

4

News

Latest

News / Media

Jan 13, 2021

Astellas Announces a Research Collaboration with Actinium for Molecular Targeted Radiotherapy

News / Media

Dec 25, 2020

Hold lifted by FDA on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM)

News / Media

Dec 07, 2020

KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus

News / Therapeutic Area News

Jan 06, 2021

FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients

News / Therapeutic Area News

Dec 21, 2020

Astellas Reports XOSPATA® (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy

News / Corporate

Dec 14, 2020

Astellas and MBC BioLabs Announce Winners of Golden Ticket Competition to Support Biotech Start-ups Accelerate Early Drug Discovery and Innovation